Rationale and Design of the ATHENA-HF Trial: Aldosterone Targeted Neurohormonal Combined With Natriuresis Therapy in Heart Failure

JACC: Heart Failure

Volumn 4, Issue 9, 2016, Pages 726-735

  Butler, Javed ^a   Hernandez, Adrian F ^b   Anstrom, Kevin J ^b   Kalogeropoulos, Andreas ^c   Redfield, Margaret M ^d   Konstam, Marvin A ^e   Tang, W H Wilson ^f   Felker, G Michael ^b   Shah, Monica R ^g   Braunwald, Eugene ^h  

^a STONY BROOK UNIVERSITY   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MAYO CLINIC   (United States)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f LERNER RESEARCH INSTITUTE   (United States)

^g NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

acute heart failure; aldosterone; heart failure; hospitalization; mineralocorticoid receptor antagonist; natriuretic peptides

Indexed keywords

ALDOSTERONE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; PLACEBO; SPIRONOLACTONE; BRAIN NATRIURETIC PEPTIDE; LOOP DIURETIC AGENT; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ACUTE HEART FAILURE; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; GLOMERULUS FILTRATION RATE; HUMAN; HYPERALDOSTERONISM; HYPERKALEMIA; HYPOKALEMIA; KIDNEY FUNCTION; LENGTH OF STAY; LOW DRUG DOSE; MORTALITY; NATRIURESIS; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM ABSORPTION; STUDY DESIGN; URINE VOLUME; VASCULAR DISEASE; VISUAL ANALOG SCALE; WEIGHT CHANGE; ACUTE DISEASE; BLOOD; CAUSE OF DEATH; CHEMICALLY INDUCED; COMPLICATION; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; HEART FAILURE; HOSPITAL READMISSION; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ACUTE DISEASE; CAUSE OF DEATH; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; DYSPNEA; HEART FAILURE; HUMANS; HYPERKALEMIA; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MORTALITY; NATRIURETIC PEPTIDE, BRAIN; PATIENT READMISSION; PEPTIDE FRAGMENTS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; SPIRONOLACTONE; TREATMENT OUTCOME;

EID: 84981736365     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2016.06.003     Document Type: Review

References (44)

1. 1 Lloyd-Jones, D., Adams, R.J., Brown, T.M., et al. Heart disease and stroke statistics–2010 update: a report from the American Heart Association. Circulation 121 (2010), e46–e215.
2. 2 Lloyd-Jones, D., Adams, R., Carnethon, M., et al. Heart disease and stroke statistics–2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119 (2009), 480–486.
3. 3 Felker, G.M., Leimberger, J.D., Califf, R.M., et al. Risk stratification after hospitalization for decompensated heart failure. J Cardiac Fail 10 (2004), 460–466.
4. 4 Massie, B.M., O'Connor, C.M., Metra, M., et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 363 (2010), 1419–1428.
5. 5 Chin, M.H., Goldman, L., Correlates of early hospital readmission or death in patients with congestive heart failure. Am J Cardiol 79 (1997), 1640–1644.
6. 6 Yamokoski, L.M., Hasselblad, V., Moser, D.K., et al. Prediction of rehospitalization and death in severe heart failure by physicians and nurses of the ESCAPE trial. J Cardiac Fail 13 (2007), 8–13.
7. 7 Krumholz, H.M., Merrill, A.R., Schone, E.M., et al. Patterns of hospital performance in acute myocardial infarction and heart failure 30-day mortality and readmission. Circ Cardiovasc Qual Outcomes 2 (2009), 407–413.
8. 8 Felker, G.M., Pang, P.S., Adams, K.F., et al. Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward. Circ Heart Fail 3 (2010), 314–325.
9. 9 Vaduganathan, M., Greene, S.J., Ambrosy, A.P., Gheorghiade, M., Butler, J., The disconnect between phase II and phase III trials of drugs for heart failure. Nat Rev Cardiol 10 (2013), 85–97.
10. 10 Gheorghiade, M., Filippatos, G., Reassessing treatment of acute heart failure syndromes: the ADHERE Registry. Eur Heart J Suppl 7 (2005), B13–B19.
11. 11 Gheorghiade, M., Vaduganathan, M., Fonarow, G.C., Bonow, R.O., Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol 61 (2013), 391–403.
12. 12 Ambrosy, A.P., Pang, P.S., Khan, S., et al. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. Eur Heart J 34 (2013), 835–843.
13. 13 Lala, A., McNulty, S.E., Mentz, R.J., et al. Relief and recurrence of congestion during and after hospitalization for acute heart failure: insights from Diuretic Optimization Strategy Evaluation in Acute Decompensated Heart Failure (DOSE-AHF) and Cardiorenal Rescue Study in Acute Decompensated Heart Failure (CARESS-HF). Circ Heart Fail 8 (2015), 741–748.
14. 14 Pimenta, J., Paulo, C., Mascarenhas, J., et al. BNP at discharge in acute heart failure patients: is it all about volemia? A study using impedance cardiography to assess fluid and hemodynamic status. Int J Cardiol 145 (2010), 209–214.
15. 15 Drazner, M.H., Hellkamp, A.S., Leier, C.V., et al. Value of clinician assessment of hemodynamics in advanced heart failure: the ESCAPE trial. Circ Heart Fail 1 (2008), 170–177.
16. 16 Girerd, N., Pang, P.S., Swedberg, K., et al. Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial. Eur J Heart Fail 15 (2013), 1228–1235.
17. 17 Abdallah, J.G., Schrier, R.W., Edelstein, C., Jennings, S.D., Wyse, B., Ellison, D.H., Loop diuretic infusion increases thiazide-sensitive Na(+)/Cl(-)-cotransporter abundance: role of aldosterone. J Am Soc Nephrol 12 (2001), 1335–1341.
18. 18 Mentz, R.J., Stevens, S.R., DeVore, A.D., et al. Decongestion strategies and renin-angiotensin-aldosterone system activation in acute heart failure. J Am Coll Cardiol HF 3 (2015), 97–107.
19. 19 Bansal, S., Lindenfeld, J., Schrier, R.W., Sodium retention in heart failure and cirrhosis: potential role of natriuretic doses of mineralocorticoid antagonist?. Circ Heart Fail 2 (2009), 370–376.
20. 20 RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 78 (1996), 902–907.
21. 21 Hensen, J., Abraham, W.T., Durr, J.A., Schrier, R.W., Aldosterone in congestive heart failure: analysis of determinants and role in sodium retention. Am J Nephrol 11 (1991), 441–446.
22. 22 van Vliet, A.A., Donker, A.J., Nauta, J.J., Verheugt, F.W., Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol 71 (1993), 21a–28a.
23. 23 Ferreira, J.P., Santos, M., Almeida, S., Marques, I., Bettencourt, P., Carvalho, H., Mineralocorticoid receptor antagonism in acutely decompensated chronic heart failure. Eur J Intern Med 25 (2014), 67–72.
24. 24 Chamsi-Pasha, M.A., Dupont, M., Al Jaroudi, W.A., Tang, W.H., Utilization pattern of mineralocorticoid receptor antagonists in contemporary patients hospitalized with acute decompensated heart failure: a single-center experience. J Cardiac Fail 20 (2014), 229–235.
25. 25 Seawell, M.R., Al Darazi, F., Farah, V., et al. Mineralocorticoid receptor antagonism confers cardioprotection in heart failure. Curr Heart Fail Rep 10 (2013), 36–45.
26. 26 Kolkhof, P., Borden, S.A., Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics. Mol Cell Endocrinol 350 (2012), 310–317.
27. 27 Sica, D.A., Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev 10 (2005), 23–29.
28. 28 Shchekochikhin, D., Lindenfeld, J., Schrier, R., Increased spironolactone in advanced heart failure: effect of doses greater than 25 mg/day on plasma potassium concentration. Cardiorenal Med 3 (2013), 1–6.
29. 29 Bettencourt, P., Azevedo, A., Pimenta, J., Frioes, F., Ferreira, S., Ferreira, A., N-terminal-pro-brain natriuretic peptide predicts outcome after hospital discharge in heart failure patients. Circulation 110 (2004), 2168–2174.
30. 30 O'Brien, R.J., Squire, I.B., Demme, B., Davies, J.E., Ng, L.L., Pre-discharge, but not admission, levels of NT-proBNP predict adverse prognosis following acute LVF. Eur J Heart Fail 5 (2003), 499–506.
31. 31 Mentz, R.J., Hernandez, A.F., Stebbins, A., et al. Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. Eur J Heart Fail 15 (2013), 456–464.
32. 32 Filippatos, G., Teerlink, J.R., Farmakis, D., et al. Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. Eur Heart J 35 (2014), 1041–1050.
33. 33 Packer, M., Colucci, W., Fisher, L., et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. J Am Coll Cardiol HF 1 (2013), 103–111.
34. 34 Konstam, M.A., Gheorghiade, M., Burnett, J.C. Jr., et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297 (2007), 1319–1331.
35. 35 Chen, J., Normand, S.L., Wang, Y., Krumholz, H.M., National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998-2008. JAMA 306 (2011), 1669–1678.
36. 36 Mozaffarian, D., Benjamin, E.J., Go, A.S., et al. Executive Summary: Heart Disease and Stroke Statistics–2016 Update: A Report From the American Heart Association. Circulation 133 (2016), 447–454.
37. 37 Butler, J., Gheorghiade, M., Kelkar, A., et al. In-hospital worsening heart failure. Eur J Heart Fail 17 (2015), 1104–1113.
38. 38 Weatherley, B.D., Milo-Cotter, O., Felker, G.M., et al. Early worsening heart failure in patients admitted with acute heart failure–a new outcome measure associated with long-term prognosis?. Fundament Clin Pharmacol 23 (2009), 633–639.
39. 39 Adams, K.F. Jr., Fonarow, G.C., Emerman, C.L., et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149 (2005), 209–216.
40. 40 Logeart, D., Tabet, J.Y., Hittinger, L., et al. Transient worsening of renal function during hospitalization for acute heart failure alters outcome. Int J Cardiol 127 (2008), 228–232.
41. 41 Bart, B.A., Goldsmith, S.R., Lee, K.L., et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 367 (2012), 2296–2304.
42. 42 Schafer, J.L., Multiple imputation: a primer. Stat Methods Medical Res 8 (1999), 3–15.
43. 43 Pfeffer, M.A., Claggett, B., Assmann, S.F., et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation 131 (2015), 34–42.
44. 44 Pitt, B., Anker, S.D., Bohm, M., et al. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. Eur J Heart Fail 17 (2015), 224–232.